Pharmaceutical

Coherus offloads Humira biosimilar Yusimry for $40m

Hong Kong King-Friend Industrial has acquired worldwide rights to Yusimry, and its subsidiary, Meitheal, will market the therapy in the US.

Jun 30, 2024 - 04:00
Coherus offloads Humira biosimilar Yusimry for $40m
Hong Kong King-Friend Industrial has acquired worldwide rights to Yusimry, and its subsidiary, Meitheal, will market the therapy in the US.
Read the original article

Tags:

Previous Article

Amylyx ventures into metabolic diseases market with $35.1m deal

Next Article

Can routinely collected primary care data drive life sciences investment in the UK?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Can pharma overcome generative AI’s bias problem?

Can pharma overcome generative AI’s bias problem?

Apr 3, 2024

MSD closes $1.3bn EyeBio acquisition, plans pivotal trial for lead asset

MSD closes $1.3bn EyeBio acquisition, plans pivotal tri...

Jul 14, 2024

Alternative therapies are needed to combat the impending threat of AMR

Alternative therapies are needed to combat the impendin...

Feb 6, 2024